Examining Molecular Differences in PDE4 Inhibitors in Pediatric Patients with Plaque Psoriasis

Key Takeaways

Roflumilast is used for COPD, reducing exacerbations but may cause gastrointestinal side effects.
Apremilast is indicated for psoriatic arthritis and plaque psoriasis, with immunomodulatory effects and a favorable safety profile.
Both PDE4 inhibitors necessitate careful patient selection and monitoring due to potential side effects.

Experts in the management of depression provide insights into understanding medication mechanisms, assessing when treatments are effective, and navigating therapy adjustments to optimize outcomes and complement various MOAs

EP: 1.Expert Insights into Navigating MDD Prevalence, Stigma, and Treatment Challenges for Improved Patient Outcomes

EP: 2.Advancing MDD Treatment: From STAR*D Insights to Precision Medicine and Novel Therapeutics

EP: 3.Commentary on Redefining Depression Management with Updated Treatment Strategies

EP: 4.Navigating Non-Response: A Holistic Approach to Patient Care

EP: 5.Transforming MDD: A Patient's Journey with Rapid-Acting Therapy

EP: 6.Quantifying Success: Measuring Depth of Treatment Response in MDD

EP: 7.Access Challenges: Bridging Insurance Gaps for MDD Innovations

Now Viewing

EP: 8.Examining Molecular Differences in PDE4 Inhibitors in Pediatric Patients with Plaque Psoriasis

Video content above is prompted by the following:

Currently there are two approved PDE4 inhibitors in this category. Could you provide an overview of these systemic treatments, highlighting their key differences and considerations in terms of efficacy and safety?ts?